Abstract
Presence of prosthetic heart valve or significant valvular heart disease (defined as: mitral stenosis, moderate or severe aortic stenosis, or severe mitral regurgitation). Active malignancy. Life expectancy < 12 months. An existing clinical indication for OAC treatment other than AF (e.g. venous thromboembolism, hypercoagulable disorders) Prior participation in an OAC randomized trial. Statistical Analysis Plan: Agreement between physician-reported and score-derived risks was reported by the weighted kappa with 95% confidence intervals (CI). Weighted kappa values of 0.01-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80, and 0.81-0.99 represent slight, fair, moderate, good, and excellent agreement, respectively. The weighted kappa was used since the categorization of bleeding and stroke risk consisted of 3 levels (low, moderate, high).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
